Mr. Pekka Kaivola, Senior Vice President responsible for the Global Sales line function of the Orion Group and member of the Executive Management Board of the Orion Group will retire on 31 December 2010. He will leave his present position as of 1 October 2010, continuing as Senior Advisor until his retirement and reporting to the President and CEO of Orion Corporation. When stepping down from the position of Senior Vice President responsible for the Global Sales line function, Mr. Kaivola will also step down from the Executive Management Board.
Mrs. Satu Ahomäki, M.Sc. (Econ.), currently Senior Vice President responsible for Orion's Animal Health business division and member of the Executive Management Board of the Orion Group, has been appointed Senior Vice President responsible for the Global Sales line function, as of 1 October 2010. Mrs. Ahomäki will continue as a member of the Executive Management Board also in her new position.
A new head who will report to a member of the Executive Management Board, will be appointed for the Animal Health business.
Timo Lappalainen, President and CEO, says:
"Pekka Kaivola has served the Orion Group since 1989, having successfully headed the company's sales operations which, under his management, have profitably evolved into a European-wide organization. I am happy to have him available for the company until the end of the year.
Satu Ahomäki is an experienced Orion colleague who has led the European expansion of our Animal Health business. Her experience from the different fields of pharmaceutical industry is important for us in the accelerating changes of the business."
The CV of Satu Ahomäki is available on the homepage of Orion, at www.orion.fi/emb-members.
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Timo Lappalainen, President and CEO, phone +358 50 966 3692
Orionintie 1A, FI-02200 Espoo
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2009 amounted to EUR 772 million. The Company invested EUR 95 million in research and development. At the end of 2009, the Group had a total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.